BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10

• Press Releases

  Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

  September 9, 2025

   · 

  10 min read
• Press Releases

  MadSci Announces $10 Million Oversubscribed Seed Financing to Advance Smart Technology for Neurologic Conditions

  September 9, 2025

   · 

  3 min read
• Press Releases

  I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments

  September 9, 2025

   · 

  8 min read
• Press Releases

  Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

  September 9, 2025

   · 

  4 min read
• Press Releases

  Pelthos Therapeutics to Participate in Upcoming September 2025 Investor Conferences

  September 9, 2025

   · 

  1 min read
• Press Releases

  IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

  September 9, 2025

   · 

  6 min read
• Press Releases

  AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

  September 9, 2025

   · 

  4 min read
• Press Releases

  Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

  September 9, 2025

   · 

  5 min read
• Press Releases

  Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

  September 9, 2025

   · 

  7 min read
• Press Releases

  BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

  September 9, 2025

   · 

  8 min read